Quest launches "most comprehensive" colorectal cancer gene test
This article was originally published in Clinica
Quest Diagnostics has launched its EGFR Pathway test for mutations that affect colorectal cancer patients' response to EGFR-inhibiting drugs, such as Amgen's Vectibix. Quest's product detects mutations in the KRAS, NRAS and BRAF genes, whereas similar tests only identify KRAS mutations. These are found in around 40% of colorectal cancer patients, and are associated with a poor response to EGFR inhibitors. However, these drugs are not effective in all patients with normal KRAS – 5% and 8% of patients with normal KRAS genes are thought to carry NRAS and BRAF mutations, respectively, which are also linked to a poor response. Madison, New Jersey-based Quest claims that EGFR Pathway provides the most comprehensive data available on KRAS, NRAS and BRAF mutations from a single test.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.